COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

1. Novavax reported Q1 2025 sales of $667 million, significantly beating forecasts. 2. Nuvaxovid sales surged to $608 million, up from $82 million last year. 3. Earnings per share rose to $2.93, surpassing Wall Street estimates. 4. Ongoing partnership with Sanofi crucial for future revenue projections. 5. FDA approval timeline remains uncertain due to additional clinical data requests.